OMERS ADMINISTRATION Corp Reduces Position in Kenvue Inc. $KVUE

OMERS ADMINISTRATION Corp trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 18.6% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 560,804 shares of the company’s stock after selling 128,300 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Kenvue were worth $11,738,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Renaissance Capital LLC boosted its position in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after purchasing an additional 48,267 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after purchasing an additional 16,164 shares during the period. Arlington Partners LLC bought a new position in shares of Kenvue in the 2nd quarter worth approximately $2,110,000. Cornell Pochily Investment Advisors Inc. boosted its holdings in shares of Kenvue by 144.6% in the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock worth $694,000 after buying an additional 19,609 shares during the last quarter. Finally, AG2R LA Mondiale Gestion D Actifs bought a new stake in Kenvue during the first quarter valued at approximately $1,725,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.5%

KVUE opened at $17.31 on Monday. The stock has a market cap of $33.15 billion, a price-to-earnings ratio of 23.07 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The firm’s fifty day moving average is $16.06 and its 200 day moving average is $19.54. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the prior year, the business posted $0.28 EPS. Kenvue’s revenue for the quarter was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on KVUE shares. Citigroup decreased their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, October 9th. Barclays upped their price objective on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Bank of America decreased their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, October 8th. Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Finally, Jefferies Financial Group reduced their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.